1. Home
  2. ADVM vs NCSM Comparison

ADVM vs NCSM Comparison

Compare ADVM & NCSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADVM
  • NCSM
  • Stock Information
  • Founded
  • ADVM 2006
  • NCSM 2006
  • Country
  • ADVM United States
  • NCSM United States
  • Employees
  • ADVM N/A
  • NCSM N/A
  • Industry
  • ADVM Biotechnology: Biological Products (No Diagnostic Substances)
  • NCSM Oilfield Services/Equipment
  • Sector
  • ADVM Health Care
  • NCSM Energy
  • Exchange
  • ADVM Nasdaq
  • NCSM Nasdaq
  • Market Cap
  • ADVM 94.6M
  • NCSM 76.3M
  • IPO Year
  • ADVM 2014
  • NCSM 2017
  • Fundamental
  • Price
  • ADVM $4.31
  • NCSM $36.70
  • Analyst Decision
  • ADVM Buy
  • NCSM
  • Analyst Count
  • ADVM 5
  • NCSM 0
  • Target Price
  • ADVM $16.60
  • NCSM N/A
  • AVG Volume (30 Days)
  • ADVM 1.0M
  • NCSM 13.1K
  • Earning Date
  • ADVM 11-07-2025
  • NCSM 10-29-2025
  • Dividend Yield
  • ADVM N/A
  • NCSM N/A
  • EPS Growth
  • ADVM N/A
  • NCSM N/A
  • EPS
  • ADVM N/A
  • NCSM 4.53
  • Revenue
  • ADVM $1,000,000.00
  • NCSM $178,000,000.00
  • Revenue This Year
  • ADVM $1,191.10
  • NCSM $11.91
  • Revenue Next Year
  • ADVM N/A
  • NCSM $7.63
  • P/E Ratio
  • ADVM N/A
  • NCSM $8.37
  • Revenue Growth
  • ADVM N/A
  • NCSM 16.49
  • 52 Week Low
  • ADVM $1.78
  • NCSM $20.00
  • 52 Week High
  • ADVM $8.18
  • NCSM $53.69
  • Technical
  • Relative Strength Index (RSI)
  • ADVM 50.55
  • NCSM 41.25
  • Support Level
  • ADVM $4.18
  • NCSM $35.06
  • Resistance Level
  • ADVM $4.37
  • NCSM $41.75
  • Average True Range (ATR)
  • ADVM 0.20
  • NCSM 2.94
  • MACD
  • ADVM -0.03
  • NCSM -0.26
  • Stochastic Oscillator
  • ADVM 51.58
  • NCSM 24.37

About ADVM Adverum Biotechnologies Inc.

Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.

About NCSM NCS Multistage Holdings Inc.

NCS Multistage Holdings Inc is a provider of engineered products and support services that facilitate the optimization of oil and natural gas well construction, well completions and field development strategies. NCS provides its products and services to exploration and production companies for use in onshore wells, predominantly wells that have been drilled with horizontal laterals in unconventional oil and natural gas formations. The company's offering is its fracturing systems products and services, which enable efficient pinpoint stimulation: the process of individually stimulating each entry point into a formation targeted by an oil or natural gas well. It sell products and services in North America and in selected international markets.

Share on Social Networks: